Teknor Apex, one of the largest privately held plastics compounders in the world, has acquired the assets of bankrupt Danimer Scientific for approximately $19 million. The Danimer Scientific acquisition transfers ownership of Danimer’s pioneering polyhydroxyalkanoate (PHA) bioplastics technology — including its flagship Nodax brand — to a company with deep expertise in compounding, distribution, and large-scale polymer processing. The deal closes a turbulent chapter for Danimer while potentially opening a new one for commercially viable PHA production.
Background: Danimer’s Rise and Fall
Danimer Scientific was once the most prominent name in PHA bioplastics. Founded in Bainbridge, Georgia, the company developed a family of PHA resins marketed under the Nodax brand, positioning them as fully biodegradable alternatives to conventional plastics for applications ranging from food packaging to drinking straws and coatings. The company went public in 2020 through a SPAC merger, reaching a peak market capitalization of over $8 billion.
However, the years that followed were difficult. Danimer faced allegations of overstating the biodegradability of its products, leading to an SEC investigation and securities fraud lawsuits. Production scale-up proved slower and more costly than projected. By late 2024, mounting losses and debt forced Danimer to file for Chapter 11 bankruptcy protection.
The bankruptcy proceedings attracted several potential buyers, but it was Teknor Apex that ultimately prevailed with its $19 million bid — a fraction of the billions in market value Danimer once commanded. For more context on the PHA material family, see our Bio-based Polymers overview.
Key Details: What Teknor Apex Is Buying
The acquisition includes Danimer’s intellectual property portfolio related to PHA production, its manufacturing equipment and facility assets, the Nodax brand name, and key customer and supplier relationships. Teknor Apex has indicated it intends to integrate PHA technology into its broader product portfolio.
Teknor Apex, headquartered in Pawtucket, Rhode Island, operates over 30 manufacturing facilities across North America, Europe, and Asia. The company generates estimated annual revenues exceeding $1.5 billion. Unlike Danimer, which was a single-product startup reliant on external funding, Teknor Apex is a diversified, financially stable compounder with decades of experience scaling polymer production.
Industry Impact: A New Chapter for PHA
The Danimer Scientific acquisition by Teknor Apex could prove pivotal for the PHA bioplastics segment. As an established compounder, the company already has the infrastructure, customer relationships, and technical expertise to blend PHA with other polymers, creating formulations tailored for specific applications.
Rather than marketing pure PHA resin — which remains expensive relative to conventional plastics — Teknor Apex can offer PHA-based compounds that balance biodegradability with cost and performance. This compounding approach has historically been the pathway through which many specialty polymers have achieved mainstream adoption.
Competitors in the PHA space — including Kaneka, Newlight Technologies, and CJ Bio — will be watching closely. The broader Market & Trends picture for bioplastics suggests growing demand, but the PHA segment still needs to prove it can deliver at scale.
What’s Next: Integration and Scale-Up
Teknor Apex has not yet disclosed detailed plans for how it will integrate Danimer’s PHA technology. Key questions remain about whether the company will restart production at Danimer’s existing facilities, invest in new capacity, or focus initially on compounding PHA with other materials.
Industry observers expect Teknor Apex to take a measured approach, focusing first on high-value applications — such as compostable food packaging, agricultural films, and marine-degradable products — before pursuing large-volume commodity markets.
The Danimer Scientific acquisition represents a second chance for Nodax PHA technology under more disciplined ownership. For a deeper look at how PHA fits into the end-of-life landscape, visit our Knowledge Zone.
